Pulmonx Corporation
LUNG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.47 | -12.65 | -0.30 | -0.48 |
| FCF Yield | -12.42% | -7.93% | -14.84% | -3.89% |
| EV / EBITDA | -4.94 | -8.02 | -4.20 | -22.24 |
| Quality | ||||
| ROIC | -40.89% | -39.11% | -32.46% | -21.66% |
| Gross Margin | 74.00% | 73.90% | 74.29% | 73.59% |
| Cash Conversion Ratio | 0.56 | 0.62 | 0.77 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.01% | 12.36% | 17.91% | 14.10% |
| Free Cash Flow Growth | 14.14% | 17.21% | -2.98% | -42.84% |
| Safety | ||||
| Net Debt / EBITDA | 0.28 | 0.76 | 1.38 | 2.62 |
| Interest Coverage | -16.45 | -19.16 | -55.01 | -57.06 |
| Efficiency | ||||
| Inventory Turnover | 1.29 | 1.07 | 0.95 | 0.79 |
| Cash Conversion Cycle | 279.33 | 379.68 | 397.80 | 469.19 |